Lexeo Therapeutics Inc (LXEO) Actualités

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic...

Form 3 - Initial statement of beneficial ownership of securities

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic...

Form S-3 - Registration statement under Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form EFFECT - Notice of Effectiveness